For the year ending 2025-12-31, BEAM made $139,743K in revenue. -$79,560K in net income. Net profit margin of -56.93%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| License and collaboration revenue | 139,743 | |||
| Research and development | 409,618 | |||
| General and administrative | 113,818 | |||
| Total operating expenses | 523,436 | |||
| Loss from operations | -383,693 | |||
| Change in fair value of derivative liabilities | 700 | |||
| Change in fair value of non-controlling equity investments | 3,942 | |||
| Change in fair value of contingent consideration liabilities | -180 | |||
| Gain on sale of equity method investment | 255,146 | |||
| Interest and other income (expense), net | 43,733 | |||
| Total other income (expense) | 303,701 | |||
| Net loss before income taxes | -79,992 | |||
| Net loss | -79,992 | |||
| Unrealized gain (loss) on marketable securities | 432 | |||
| Comprehensive loss | -79,560 | |||
| Basic EPS | -0.81 | |||
| Diluted EPS | -0.81 | |||
| Basic Average Shares | 98,905,577 | |||
| Diluted Average Shares | 98,905,577 | |||
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)